Since previous studies show that other ROS-inducing antineoplastic agents inhibit growth and survival of RCC [42, 43], the induction of ROS by C-DIM/NR4A1 antagonists contributed to the anticancer activity of these compounds. The gene discussed is NR4A1; the disease is renal cell adenocarcinoma.